Clinical Trial

Efficacy and Safety of Standard of Care Plus Durvalumab in Patients With Limited Disease Small Cell Lung Cancer (DOLPHIN)

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Combination of concomitant Radio-Chemotherapy showed a significant improvement (Takada) of OS and PFS in limited disease SCLC patients. This clinical trial is a prospective, multicenter, randomized, open-label, parallel group phase II investigator initiated trial (ITT) to evaluate the efficacy and safety of Durvalumab in combination with Cisplatin/Etoposide/Radiotherapy in patients with limited disease small-cell lung cancer (SCLC).
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2020-10-23; most recent amendment 2026-02-25.
Status change: Recruiting → Active, Not Recruiting 2025-08-13
Status change: Not Yet Recruiting → Recruiting 2021-01-13
Trial Details
NCT Number NCT04602533
Lead Sponsor Michael Hopp
Collaborators: AstraZeneca
Conditions Small Cell Lung Cancer Limited Stage
Enrollment 105 participants
Start Date 2020-12-21
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-02-27